BOSTON ( TheStreet) -- The American Society of Clinical Oncology (ASCO) annual meeting, held this year June 4-8, brings together cancer drug researchers from all over the world to discuss and present new clinical data aimed at treating -- and maybe one day curing -- cancer. The ASCO annual meeting also attracts investors in almost equal numbers because treating cancer is big business. Wall Street pays close attention because the ASCO meeting moves biotech and drug stocks, often well before the ASCO confab even gets started. Toxic Supplements (Forbes) I've assembled a list of biotech and drug stocks that will be presenting new clinical data at this year's ASCO meeting. The list isn't exhaustive, but covers stocks that will likely receive the most investor attention at the meeting. (And as I point out, many of these stocks have already started to run up as the ASCO meeting approaches.) ASCO has already posted online the research abstract titles for this year's meeting. On May 20 at 6 p.m. EDT, ASCO will post the content of those abstracts, which will contain more information about the data to be presented.
Curis ( CRIS)Drug: GDC-0449 Abstract No. 3530 Indication: colorectal cancer Clinical Trial: Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 vs. placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC). Presentation Time: Tuesday, June 8. Poster session. Notes:GDC-0449 is partnered with Roche/Genentech.
More on Biotech
|14 Biotech Stocks Facing FDA Approval |